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Androgen biosynthesis in the human fetus proceeds through the
adrenal sex steroid precursor dehydroepiandrosterone, which is
converted to testosterone in the gonads, followed by further activa-
tion to 5α-dihydrotestosterone in genital skin, thereby facilitating
male external genital differentiation. Congenital adrenal hyperplasia
due to P450 oxidoreductase deficiency results in disrupted dehydro-
epiandrosterone biosynthesis, explaining undervirilization in affected
boys. However, many affected girls are born virilized, despite low
circulating androgens. We hypothesized that this is due to a prena-
tally active, alternative androgen biosynthesis pathway from 17α-
hydroxyprogesterone to 5α-dihydrotestosterone, which bypasses
dehydroepiandrosterone and testosterone, with increased activity
in congenital adrenal hyperplasia variants associated with 17α-
hydroxyprogesterone accumulation. Here we employ explant cul-
tures of human fetal organs (adrenals, gonads, genital skin) from
the major period of sexual differentiation and show that alternative
pathway androgen biosynthesis is active in the fetus, as assessed by
liquid chromatography–tandem mass spectrometry. We found andro-
gen receptor expression in male and female genital skin using immu-
nohistochemistry and demonstrated that both 5α-dihydrotestosterone
and adrenal explant culture supernatant induce nuclear transloca-
tion of the androgen receptor in female genital skin primary cultures.
Analyzing urinary steroid excretion by gas chromatography–mass
spectrometry, we show that neonates with P450 oxidoreductase de-
ficiency produce androgens through the alternative androgen path-
way during the first weeks of life. We provide quantitative in vitro
evidence that the corresponding P450 oxidoreductasemutations pre-
dominantly support alternative pathway androgen biosynthesis.
These results indicate a key role of alternative pathway androgen
biosynthesis in the prenatal virilization of girls affected by con-
genital adrenal hyperplasia due to P450 oxidoreductase deficiency.
fetal androgen biosynthesis | congenital adrenal hyperplasia | alternative
androgen pathway | 5α-dihydrotestosterone | human sexual differentiation
Gonadal development depends on chromosomal sex, wherebythe 46,XY or 46,XX karyotype, established at fertilization,
dictates subsequent development of either testis or ovary (1–3).
Gonadal hormones then direct differentiation of either male or
female genitalia. In humans, sexual differentiation is established
at 7 to 12 wk post conception (wpc) (4).
While secretion of testosterone by fetal testis Leydig cells is
thought sufficient to drive virilization of the internal genitalia in
the male fetus (5), differentiation of the external genitalia re-
quires the action of 5α-dihydrotestosterone (DHT), which is gen-
erated locally from circulating testosterone by the enzyme steroid
5α-reductase type 2 (SRD5A2) (6, 7). By contrast, differentiation
of human female genitalia has been regarded as the default of a
low-androgen environment.
In humans, the regulation of sexual differentiation is intricately
linked to early development of the adrenal cortex (4, 8). Disorders
affecting adrenal steroidogenesis commonly affect sexual differen-
tiation, as exemplified by the multiple variants of congenital adrenal
hyperplasia (CAH), which result either in inappropriate or disrupted
androgen biosynthesis. This consequently causes disorders of sex
development (DSDs), which can manifest with external genital
virilization in newborn girls (46,XX DSD) or undermasculinization
of external genitalia in male neonates (46,XY DSD) (9). The
most common variant of CAH, 21-hydroxylase (CYP21A2) de-
ficiency, manifests with 46,XX DSD, while 17α-hydroxylase/17,20-
lyase (CYP17A1) deficiency results in 46,XY DSD.
The congenital adrenal hyperplasia variant cytochrome P450
oxidoreductase (POR) deficiency can manifest with both 46,XY
Significance
In the classic androgen biosynthesis pathway, testosterone is
converted to 5α-dihydrotestosterone, a step crucially required
for normal male genital virilization. Congenital adrenal hyper-
plasia (CAH) due to P450 oxidoreductase deficiency (PORD) is an
inborn disorder that disrupts classic androgen biosynthesis.
However, some affected girls present with severe genital viri-
lization at birth. We hypothesized that this is explained by
a prenatally active, alternative biosynthesis pathway to 5α-
dihydrotestosterone. We show that adrenals and genital skin
cooperate to produce androgens via the alternative pathway
during the major period of human sexual differentiation and
that neonates with PORD still produce alternative pathway an-
drogens during the first weeks of life. This indicates that alter-
native pathway androgen biosynthesis drives prenatal virilization
in CAH due to PORD.
Author contributions: N.R., A.E.T., E.F.N., D.J.A., C.H.L.S., N.A.H., and W.A. designed re-
search; N.R., A.E.T., E.F.N., D.J.A., V.D., A.B., and N.K. performed research; R.J.A. contrib-
uted new reagents/analytic tools; N.R., A.E.T., E.F.N., D.J.A., V.D., A.B., N.K., C.H.L.S.,
N.A.H., and W.A. analyzed data; N.R., N.A.H., and W.A. wrote the paper; and V.D.,
A.B., N.K., R.J.A., and C.H.L.S. contributed to the writing of the paper.
The authors declare no competing interest.
This article is a PNAS Direct Submission. M.B.R. is a guest editor invited by the
Editorial Board.
This open access article is distributed under Creative Commons Attribution License 4.0
(CC BY).
1N.R., A.E.T., E.F.N., and D.J.A. contributed equally to this work.
2N.A.H. and W.A. contributed equally to this work.
3To whom correspondence may be addressed. Email: w.arlt@bham.ac.uk.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1906623116/-/DCSupplemental.
First published October 14, 2019.
22294–22299 | PNAS | October 29, 2019 | vol. 116 | no. 44 www.pnas.org/cgi/doi/10.1073/pnas.1906623116
D
ow
nl
oa
de
d 
at
 U
ni
ve
rs
ity
 o
f S
he
ffi
el
d 
Li
br
ar
y 
on
 N
ov
em
be
r 1
1,
 2
01
9 
DSD and 46,XX DSD (10–12). POR plays a pivotal role as the
obligatory electron donor to all microsomal cytochrome P450
enzymes, including CYP21A2 and CYP17A1, the latter catalyz-
ing the biosynthesis of dehydroepiandrosterone (DHEA), the
major precursor for testosterone biosynthesis. Consequently,
POR deficiency (PORD) results in low circulating androgen
concentrations, which readily account for 46,XY DSD, but fails
to account for the severe virilization of external genitalia regu-
larly observed in affected 46,XX neonates.
An explanation for this striking and seemingly contradictory
genital phenotype in PORD has been lacking. We hypothesized
that this apparent paradox could be explained by the existence of
an alternative pathway to androgen production that generates
DHT from 17α-hydroxyprogesterone (17OHP) during human
fetal sexual differentiation, thereby bypassing the classic andro-
gen biosynthesis pathway via DHEA and testosterone, as pre-
viously proposed by us (11) and others (13, 14). Elements of this
pathway have been characterized in the fetal gonad of the tam-
mar wallaby pouch young (15–17) and fetal opossum urogenital
tract (18, 19). 17OHP accumulates in PORD but also in the most
common CAH variant, 21-hydroxylase deficiency, and thus could
feed into the proposed alternative pathway, if present in the
fetus. Indirect biochemical evidence has indicated that the pro-
posed alternative pathway is active postnatally in individuals with
CAH due to 21-hydroxylase deficiency (20, 21) and may explain
maternal virilization observed in pregnancies affected by PORD
(22, 23). However, direct delineation of the putative alternative
pathway during human fetal development, and in particular during
the major period of sexual differentiation, has been lacking.
Here, we present conclusive evidence for the presence and
activity of the alternative pathway in the human fetus, producing
potent androgens during the major period of sexual differentiation,
and show that human fetal female external genitalia respond
sensitively to androgens during the same period. In concert, these
findings define an alternative pathway for androgen biosynthesis
during the critical period of sexual differentiation in the human
fetus that represents an important mechanism to explain the
prenatal virilization of female infants affected by CAH.
Results and Discussion
Androgen Biosynthesis in the Human Fetus during Sexual
Differentiation. To ascertain the presence and activity of the hy-
pothesized alternative androgen pathway, we performed incu-
bations with male and female fetal adrenals, gonads, and genital
skin, which were collected at 6 to 10 wpc as previously described
(8). We separately added deuterated steroid substrates for each
step of the alternative pathway and employed liquid chroma-
tography–tandem mass spectrometry (LC-MS/MS) to identify
the resulting products (SI Appendix, Fig. S1 and Tables S1 and
S2). Experiments were conducted at least in triplicate for each
organ of either sex (SI Appendix, Figs. S2 and S3).
Explant incubations with female tissue showed that some
17OHP entered the classic androgen biosynthesis pathway, yield-
ing androstenedione in adrenal, ovary, and genital skin. However,
testosterone was detected in only 2 of 9 female genital skin in-
cubations, and not at all in female adrenals and gonads (Fig. 1A).
By contrast, all 3 female tissues (genital skin, ovaries, and adrenals)
showed conversion of 17OHP and subsequent intermediates
through all steps of the proposed alternative androgen path-
way, with the end product, DHT, produced from 5α-androsterone,
with either 5α-androstanediol or 5α-androstanedione as interme-
diates (Fig. 1A).
Male fetal tissues readily converted 17OHP along the classic
androgen pathway to testosterone and, in the alternative pathway,
to 5α-17-hydroxypregnanolone (5α-17HP). In male genital skin,
conversion from 17OHP proceeded until the generation of DHT
A
B
Fig. 1. Androgen biosynthesis via classic and alternative androgen pathways as observed in human fetal organ explant cultures from the major period of sexual
differentiation. The steroid substrates added to the explant cultures derived from fetal adrenals, gonads, and genital skin (collected at 6 to 10 wpc) are shown in
red and blue for fetal female (A) and male (B) tissues, respectively. Conversion products detected and identified by LC-MS/MS are given in black. f, female; m,
male; n indicates the number of biological replicates per tissue and fetal sex and howmany of the cultures showed detectable synthesis of the indicated products.
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(Fig. 1B), feasibly arising from either route, as DHT represents the
end product of both the classic and alternative androgen pathways.
However, incubations with the intermediate substrates of the al-
ternative pathway demonstrated stepwise catalysis to DHT by
male adrenal, testis, and genital skin (Fig. 1B). Consistent with
studies in nonhuman species (24, 25), we did not identify 5α-
pregnane-17α-ol-3,20-dione as a significant intermediate of the
2-step conversion of 17OHP to 5α-17HP in tissues from either sex,
likely due to its immediate forward conversion.
Taken together, these data show that adrenals, gonads, and
genital skin are capable of androgen biosynthesis via both the
classic and alternative pathways in both sexes. Our data suggest
the presence of an integrated adrenogenital steroidogenic unit
capable of producing DHT during the period of sexual differ-
entiation in both male and female fetuses.
We did not study the recently described 11-oxygenated an-
drogen biosynthesis pathway (26, 27), initiated by conversion of
androstenedione to 11-hydroxyandrostenedione by CYP11B1
11β-hydroxylase activity, and eventually yielding 11-ketotestos-
terone, which activates the androgen receptor with similar po-
tency to testosterone. Recent work indicated a significant role of
11-oxygenated androgens in CAH due to 21-hydroxylase de-
ficiency (28) and polycystic ovary syndrome (29). We previously
demonstrated the presence and activity of CYP11B1 in the hu-
man fetal adrenal during the period of sexual differentiation (8),
and hence at least the initial step of the 11-oxygenated androgen
pathway is likely to occur. However, urine steroid excretion
analysis in infants with PORD (13) did not show increased ex-
cretion of 11-hydroxyandrosterone, the major metabolite derived
from 11-oxygenated androgens, indicating that this side arm of the
classic androgen pathway is unlikely to play a major role in PORD.
Steroidogenic Enzyme Expression during Human Fetal Sexual
Differentiation. The alternative pathway conversion of 17OHP to
5α-17HP requires sequential 5α-reductase and 3α-hydroxysteroid
dehydrogenase activities.
Of the 2 isoforms, the first step is expected to require catalysis
by steroid 5α-reductase type 1 (SRD5A1), since SRD5A2 does
not convert 17OHP efficiently (30). A study of fetal tissues from
12 to 20 wpc did not detect SRD5A1 in adrenals, gonads, or
genital skin (31); a recent study also using fetal tissues from the
second trimester of pregnancy (11 to 21 wpc) described detection
of SRD5A1 in liver, placenta, testis, and genital tubercle but not
in the adrenal, while female gonads were not studied (32).
However, studying tissue from the major period of human sexual
differentiation, we found mRNA expression of SRD5A1 in ad-
renals, gonads, and genital skin of both sexes (Fig. 2A). The
second step, the conversion of 5α-pregnane-17α-ol-3,20-dione to
5α-17HP, requires 3α-hydroxysteroid dehydrogenase activity, in
keeping with the observed expression of AKR1C1 and AKR1C3,
both of which encode enzymes capable of catalyzing this reaction
(Fig. 2A).
The next step in the alternative pathway requires CYP17A1
17,20-lyase activity; 5α-17HP is the preferred substrate for this
reaction and efficiently converted to 5α-androsterone (33). We
detected robust CYP17A1 expression in human fetal adrenals from
the major period of sexual differentiation, consistent with previous
reports (8, 34) and also in the gonads of both sexes (Fig. 2B). The
subsequent reduction of 5α-androsterone to 5α-androstanediol
requires 17β-hydroxysteroid dehydrogenase activity, which can be
provided by AKR1C3 or AKR1C1, expressed in adrenals, gonads,
and genital skin (Fig. 2A).
The final step of the proposed pathway involves the conver-
sion of 5α-androstanediol to DHT, which requires 3β-epimerase
(oxidative 3α-HSD) activity. Several enzymes have been consid-
ered to catalyze this reaction (i.e., AKR1C2, RDH5, DHRS9,
HSD17B10, HSD17B6, and RDH16). However, only HSD17B6
and RDH16 are capable of efficient oxidation of 5α-androstanediol
to DHT, as previously demonstrated by transactivation of the an-
drogen receptor following cell-based overexpression (24, 35). We
found expression of both HSD17B6 and RDH16 in fetal genital
skin of both sexes (Fig. 2C).
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Fig. 2. Steroidogenic enzyme expression in human fetal tissue from the major period of sexual differentiation and their proposed role(s) in alternative
pathway synthesis. (A and B) mRNA expression (mean ± SEM) in human fetal tissues collected at 6 to 10 wpc as measured by qPCR in female adrenals (n = 1),
gonads (n = 2), genital skin (n = 2), and corresponding male tissues (≥3 biological replicates for adrenals, gonads, and genital skin). (C) Fetal genital skin mRNA
expression of all enzymes potentially capable of converting 5α-androstanediol to 5α-dihydrotestosterone. Expression data were normalized to ribosomal 18S.
(D) Schematic summary of the proposed distinct roles of the identified enzymes in the classic androgen pathway (dark blue) and the alternative androgen
synthesis pathway (light blue), both resulting in the synthesis of potent 5α-dihydrotestosterone. Arrows indicate observed conversions in the fetal organ
explant cultures; dotted arrows represent reactions only rarely observed.
22296 | www.pnas.org/cgi/doi/10.1073/pnas.1906623116 Reisch et al.
D
ow
nl
oa
de
d 
at
 U
ni
ve
rs
ity
 o
f S
he
ffi
el
d 
Li
br
ar
y 
on
 N
ov
em
be
r 1
1,
 2
01
9 
In summary, we detected the transcripts encoding all enzymes
required to catalyze the alternative androgen pathway (Fig. 2D).
Taken together with the steroid conversion studies, these data
comprehensively demonstrate that the normal adrenal, gonad,
and genital skin are capable of androgen biosynthesis via both
the classic and alternative pathways in both sexes. Our data point
to an adrenogenital steroidogenic unit that can cooperate to pro-
duce DHT via the alternative pathway during the major period
of human sexual differentiation.
Androgen Receptor in Female Genitalia from the Start of Sexual
Differentiation. Having demonstrated the capacity for DHT pro-
duction from steroidogenic precursors in female fetuses, we
corroborated its ability to function by examining the presence of
the androgen receptor (AR) in female external genitalia from
the start of sexual differentiation. Previously, AR expression was
documented in 4 female human fetuses from 9 to 18 wpc (36). In
our study, we readily detected AR protein in stromal cells in the
urethral folds of the external genitalia in both male and female
fetuses at the onset of sexual differentiation (Fig. 3 A–C). Its
nuclear localization in fixed tissues in both sexes implied AR was
ligand-bound. To explore this further, we studied the intracel-
lular localization of AR by immunofluorescence in female external
genital fibroblasts taken into primary culture from the same stage
of development. In steroid-free media, the external genital cells
demonstrated cytoplasmic AR localization. As expected, the ad-
dition of 1 nM DHT induced nuclear translocation of AR. Strik-
ingly, the same translocation was observed when using medium
conditioned overnight from the corresponding female adrenal
gland (Fig. 3D). In combination, these data show AR from the
start of sexual differentiation in both male and female external
genitalia and demonstrate a functional adrenogenital steroido-
genic unit capable of causing AR nuclear translocation.
Androgen Biosynthesis in Neonates with Congenital Adrenal
Hyperplasia Due to P450 Oxidoreductase Deficiency. Having shown
evidence of the alternative pathway during human sexual dif-
ferentiation, we next investigated whether we could demonstrate
equivalent activity in vivo. To address our hypothesis that excess
alternative pathway androgen biosynthesis in fetal life explains
female virilization (46,XX DSD) in CAH due to PORD (12, 37),
in whom the classic androgen pathway is disrupted, we identified
3 patients with a mutation known to cause 46,XX DSD in af-
fected girls and facilitate normal male appearance of external
genitalia in affected boys (POR A287P) (11, 12). All 3 individuals
had a 46,XY karyotype; patients 1 and 2 harbored homozygous
A287P mutations while patient 3 was compound-heterozygous for
POR A287P/G188_V191dup. While postnatal circulating andro-
gens in PORD are low in infancy and beyond (12, 37), we hy-
pothesized that affected individuals would still show evidence of
excess alternative pathway androgen biosynthesis in the immediate
neonatal period. We analyzed urinary steroid metabolite excretion
by gas chromatography–mass spectrometry and detected signifi-
cant alternative pathway activity in the neonatal period, consistent
with previous preliminary findings that argued for the adrenal
gland as a major site for alternative pathway activity (13). During
the first 3 wk after birth, we documented increased excretion of
the 17OHP metabolite 17-HP compared with healthy controls
(Fig. 4A), consistent with accumulation of 17OHP, the initial
substrate of the alternative androgen pathway. We found signifi-
cantly increased excretion of 5α-17HP (Fig. 4B), a key intermedi-
ate of the alternative pathway; and, finally, there was significantly
increased excretion of the major DHTmetabolite 5α-androsterone
(Fig. 4C). By contrast, etiocholanolone excretion, derived from
classic pathway androgen biosynthesis, did not differ between the
affected and healthy control groups (Fig. 4D). This result corrob-
orates a previous report on urine steroid metabolite excretion in a
46,XY infant affected by PORD, which also described increased
5α-androsterone but unremarkable etiocholanolone excretion (38).
Of note, the POR A287P-homozygous patients in our study had
higher excretion of 5α-17HP and 5α-androsterone than the
compound-heterozygous patient, who can be expected to have
less alternative pathway activity due to the greater impairment of
residual POR function. Taken together, these findings indicate
increased in vivo alternative pathway androgen biosynthesis in
neonates with PORD, which ceases shortly after birth.
These findings were further supported by in vitro 17,20-lyase
activity assays employing yeast microsomes cotransformed with
human CYP17A1 and either wild-type or mutant POR. The results
demonstrated that the residual activity of POR A287P was higher
in the alternative androgen pathway than in the classic pathway.
POR A287P demonstrated significantly higher activity than POR
mutant H628P, which in the homozygous state is associated with
severe male undervirilization (46,XY DSD) and normal female
genital phenotype (SI Appendix, Fig. S1 A–C). Additional ex-
periments with yeast microsomes cotransformed with CYP19A1
and wild-type or mutant POR demonstrated that neither mutant
affected aromatase activity (SI Appendix, Fig. S1D), thus ex-
cluding impaired aromatization of classic pathway androgens as
a driver of prenatal virilization.
Fig. 3. Androgen receptor is present in both male and female genitalia
from the onset of sex differentiation. (A) Morphology of male and female
external genitalia at the onset of sex differentiation. gt, genital tubercle; lsf,
labioscrotal fold; uf, urethral fold. Asterisks indicate patency between ure-
thral folds at 7 to 8 wpc that is partially sealed in males by 10 to 11 wpc. (B
and C) Immunohistochemistry in transverse sections through the phallus for
AR in male (B) and female (C) external genitalia from the start of human
sexual differentiation at 7 to 8 wpc counterstained with toluidine blue. Boxes
(Left) are shown at higher magnification (Right). (D) Immunofluorescence for
AR in female external genital fibroblasts in the presence (+) or absence (−) of
10 nM DHT (Left) or medium conditioned by overnight incubation with an
adrenal gland from the same female fetus (Right). [Scale bars, 500 μm (A);
100 μm (low) and 20 μm (high magnification) (B and C); and 25 μm (D).]
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In conclusion, we have provided in vitro, ex vivo, and in vivo
evidence for the existence and activity of an alternative pathway
for the synthesis of the most potent androgen, DHT, during early
human development. Our data demonstrate that, through co-
operation of an adrenogenital steroidogenic unit, the alternative
androgen pathway yields active androgen synthesis in the female
fetus, with excess activity driving female virilization, 46,XX DSD,
in CAH due to P450 oxidoreductase deficiency. Given that the
alternative pathway substrate 17OHP also accumulates in 21-
hydroxylase deficiency, it is conceivable that alternative pathway
androgens contribute to prenatal virilization in this most com-
mon CAH variant.
Materials and Methods
Collection of Human Embryonic and Fetal Material. Ethical approval for these
studies was granted by the North West Haydock Research Ethics Committee
of the UK Health Research Authority (approval no. 18/NW/0096). The col-
lection and staging of human embryonic and fetal material were carried out
with informed consent, as described previously (8, 39), using Carnegie clas-
sification and fetal foot length to provide a direct assessment of develop-
mental age as days or weeks post conception (dpc or wpc), respectively, and
male fetal material was identified by SRY expression, as previously described
(1). We analyzed organs and tissue from 30 fetuses: 25 male and 5 female;
median age 55 dpc (range 44 to 84 dpc).
RNA Extraction, Reverse Transcription, and Quantitative PCR. Total RNA was
extracted from whole organs using the TRI Reagent system (Sigma-Aldrich).
RNA integrity and concentrations were assessed using a NanoDrop spec-
trophotometer. Reverse transcription was carried out employing a standard
protocol. mRNA expression levels were quantified using an ABI 7500 se-
quence detection system (PerkinElmer Applied Biosystems), employing the
Applied Biosystems “assay on demand” probe and primers for specific am-
plification of SRD5A1, SRD5A2, CYP17A1, AKR1C1, AKR1C2, AKR1C3, AKR1C4,
HADH2/HSD17B10, HSD17B6, RDH5, DHRS9, and RDH16 (for further details,
see SI Appendix).
Tissue Explant Culture and Steroid Identification by Tandem Mass
Spectrometry. Whole-organ tissue explants (fetal adrenals, gonads, and
genital skin) were cultured in DMEM/F12 (PAA Laboratories) supplemented
with 2% Ultroser SF (i.e., steroid-free; BioSepra) and 1% ITS+ (BD) at 37 °C in
humidified 5% CO2 and 95% air for 64 h. Genital skin was cultured as mono-
layers and used for experiments at passage 4.
Identification of steroid products from the explant cultures was achieved
using LC-MS/MS. Steroids were positively identified by comparison of re-
tention time and MS/MS mass transitions with authentic steroid standards (SI
Appendix, Table S1). Two mass transitions were used to positively identify
each steroid, referred to as quantifier and qualifier ions, respectively; the
resolution of a series of authentic steroid standards is shown in SI Appendix,
Fig. S2, alongside further method details.
For steroid conversion assays, tissue explants were incubated with pre-
cursor steroids purchased from Steraloids and Sigma-Aldrich. For explant
cultures assessing the conversion of 17-hydroxyprogesterone, 5α-androster-
one, and 5α-androstanediol, we used deuterated steroids (for details, see SI
Appendix, Table S2). Representative results of steroid detection following
explant culture incubations are shown in SI Appendix, Figs. S3 and S4 for fe-
male and male tissues.
Immunohistochemistry. Immunohistochemistry, immunoblotting, and immu-
nofluorescence were carried out as reported previously (40), using monoclonal
mouse anti-AR (1:100; LabVision).
Urine Steroid Metabolite Excretion Analysis. Urine samples were collected
longitudinally from birth until 90 d of life in 3 neonates affected with PORD
(2 homozygous for POR A287P, and the other 1 compound-heterozygous
for POR A287P/G188_V191dup) and compared with those collected from 9
healthy controls. These were matched for sex, age, and gestational age at
birth and collected during the same time window. The parents of PORD
patients and healthy controls provided written informed consent prior to
urine collection. The study protocol was reviewed and approved by the
Research Ethics Committee of the University College London Institute of Child
Health/Great Ormond Street Hospital NHS Trust (REC reference 05/Q0508/24).
Urinary steroid hormone profiles were determined by gas chromatogra-
phy–mass spectrometry analysis as described previously (41). The final ana-
lytical samples are the methyloxime-trimethylsilyl derivatives of steroids
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Fig. 4. Urinary steroid excretion in 3 46,XY neonates with POR deficiency (closed symbols) in comparison with 9 sex- and age-matched healthy controls (open
symbols). POR-deficient neonates harbored the A287P mutation, which in the homozygous state is associated with normal male genitalia in boys and genital
virilization (46,XX DSD).We included data from 3 46,XY neonates with PORD; 2 harbored homozygous PORmutations (A287P/A287P), and 1 harbored compound-
heterozygous mutations (A287P/G188_V191dup). Longitudinal urine collections were carried out during the first 3 mo of life and analyzed by gas chromatog-
raphy–mass spectrometry. Depicted are the urinary excretion of (A) the 17OHP metabolite 17-hydroxypregnanolone (17HP) and the 2 alternative pathway
intermediates (B) 5α-17-hydroxypregnanolone (5α-17HP) and (C) 5α-androsterone (An), in comparison with (D) etiocholanolone (Et), which is only generated via
the classic androgen pathway. All steroids are shown relative to tetrahydrocortisone (THE), an abundant adrenal-derived steroid metabolite, as the denominator.
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enzymatically released from sulfate and glucuronide conjugation. Analytes
quantified by selected ion monitoring were normalized to tetrahydrocortisone,
the most abundant steroid metabolite consistently excreted throughout life,
with no significant difference in urinary tetrahydrocortisone concentrations
identified between PORD patients (n = 3; 13 urine samples; median 285 μg/L,
range 56 to 1,256 μg/L) and healthy controls (n = 9; 48 urine samples; median
306 μg/L, range 59 to 1,663 μg/L).
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